In 2024, over 90 pivotal cardiology trials were published or presented across major global meetings (ACC, ESC, EuroPCR, TCT, AHA, EHRA, CRT, TVT, SCAI). Together, they highlight transformative updates across the spectrum of cardiovascular care. Key interventional findings included the FAVOR III trial refining coronary physiology, progress in drug-coated balloons (REGCAGE-FREE, AGENT-IDE), and advances in acute coronary syndromes (SENIOR-RITA, DanGer-Shock). Structural cardiology witnessed major steps forward with EARLY-TAVR, NOTION 3, TRISCEND II, and MATTERHORN.
Preventive cardiology advanced with novel lipoprotein(a) and LDL-C–lowering therapies, plus hypertension trials like BPROAD and KRAKEN. Heart failure and rare cardiac conditions also saw progress, including SUMMIT, FINEARTS, SEQUOIA-HCM, and HELIOS-B for cardiac amyloidosis. Together, these results underscore an ongoing…
